WW International, Inc. Q3 2025 Earnings Recap

WW Q3 2025 November 8, 2025

Get alerts when WW reports next quarter

WeightWatchers demonstrated strong resilience in Q3 2025, leveraging its integration with GLP-1 medications to enhance member outcomes, positioning itself for renewed growth in the weight management sector.

Earnings Per Share Miss

$-0.44 vs $-0.14 est.

-214.3% surprise

Revenue Beat

170929000 vs 149799500 est.

+14.1% surprise

Market Reaction

1-Day +0.0%

5-Day -14.72%

30-Day -17.55%

See WW alongside your other holdings

Add to your portfolio — free

Key Takeaways

WeightWatchers Clinic significantly improved weight loss outcomes for members using GLP-1 medications, achieving a 19% to 23% average weight loss over three years.
98% of members prescribed weight management medication experienced more than 10% weight loss within 12 months.
The company is modernizing its digital platform to enhance member experience and engagement, with a focus on AI-driven personalized solutions.
A successful financial reorganization has strengthened the balance sheet, allowing for increased investments in growth and innovation.
The demand for GLP-1 medications continues to rise, with over 12% of U.S. adults currently utilizing these treatments, highlighting a significant market opportunity.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WW on AllInvestView.

Previous Q2 2025